Cancer Family
Bone Marrow Neoplasm
CI-CAN-00000093Explore in graph →
Non-malignant1,035 active trials28 approved drugs633 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000093Explore in graph →
Clinical trials
4,615 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01461538 | Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies | completed | Phase 2 | 84 | Seagen Inc.INDUSTRY | 1 | Mar 4, 2016 | clinicaltrials |
| NCT00850382 | Dasatinib (Sprycel™) in Patients With Newly Diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) | completed | Phase 1 / Phase 2 | 89 | University of UlmOTHER | 2 | Mar 1, 2016 | clinicaltrials |
| NCT00975975 |
| Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer |
| completed |
| Phase 2 |
| 17 |
| Indiana UniversityOTHER |
| 1 |
| Feb 26, 2016 |
| clinicaltrials |
| NCT01413568 | Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies | completed | Phase 1 / Phase 2 | 38 | Polyphor Ltd.INDUSTRY | 1 | Feb 26, 2016 | clinicaltrials |
| NCT01690507 | Decitabine Combining Modified CAG Followed by HLA Haploidentical Peripheral Blood Mononuclear Cells Infusion for Elderly Patients With Acute Myeloid Leukemia(AML） | completed | Phase 1 / Phase 2 | 29 | Chinese PLA General HospitalOTHER | 1 | Feb 25, 2016 | clinicaltrials |
| NCT00349518 | Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL | withdrawn | Phase 2 / Phase 3 | 0 | Bristol-Myers SquibbINDUSTRY | 6 | Feb 17, 2016 | clinicaltrials |
| NCT01488565 | A Single Arm Pilot Study of Azacitidine in Myelodysplastic Syndromes (MDS) / Acute Myeloid Leukaemia (AML), With Eltrombopag Support for Thrombocytopenia(Aza-E) | completed | Phase 2 | 25 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Feb 15, 2016 | clinicaltrials |
| NCT00526292 | Chemotherapy and a Donor Natural Killer Cell Infusion in Treating Patients With Relapsed or Persistent Leukemia or Myelodysplastic Syndrome After a Donor Stem Cell Transplant | completed | Phase 2 | 12 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 12, 2016 | clinicaltrials |
| NCT00597519 | A Myeloablative Conditioning Regimen and Total Body Irradiation Followed by the Transplantation for Patients With Hematological Malignancy | completed | Phase 2 | 28 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 12, 2016 | clinicaltrials |
| NCT00893373 | Study Evaluating Sorafenib Added to Standard Primary Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Less Than 60 Years of Age(SORAML) | completed | Phase 2 | 276 | Technische Universität DresdenOTHER | 1 | Feb 5, 2016 | clinicaltrials |
| NCT01390402 | Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine/ATG | completed | Phase 2 | 6 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 3, 2016 | clinicaltrials |
| NCT01864902 | Treatment of Relapsed and/or Chemotherapy Refractory CD33 Positive Acute Myeloid Leukemia by CART-33(CART33) | unknown | Phase 1 / Phase 2 | 10 | Chinese PLA General HospitalOTHER | 1 | Jan 28, 2016 | clinicaltrials |
| NCT01243073 | Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera(ET/PV) | completed | Phase 2 | 20 | Geron CorporationINDUSTRY | 3 | Jan 26, 2016 | clinicaltrials |
| NCT01338337 | Study of Vidaza (Azacitidine) Versus Support Treatment in Patients With Low Risk Myelodysplastic Syndrome (Low and Intermediate-1 IPSS) Without the 5q Deletion and Transfusion Dependent Anaemia(ABRAZA) | completed | Phase 2 | 40 | Asociación Andaluza de Hematología y HemoterapiaOTHER | 1 | Jan 26, 2016 | clinicaltrials |
| NCT00014495 | Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Myeloid Cancer | completed | Phase 1 / Phase 2 | 32 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 22, 2016 | clinicaltrials |
| NCT00588666 | Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma | completed | Phase 2 | 51 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 22, 2016 | clinicaltrials |
| NCT01822691 | Phase II INCB024360 Study for Patients With Myelodysplastic Syndromes (MDS) | completed | Phase 2 | 15 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 18, 2016 | clinicaltrials |
| NCT01336712 | Total Body Irradiation/Fludarabine Based Ablative Haploidentical Transplant for Hematologic Diseases | completed | Phase 2 | 30 | Northside Hospital, Inc.OTHER | 1 | Jan 14, 2016 | clinicaltrials |
| NCT00731328 | Donor Stem Cell Transplant After Busulfan, Fludarabine, Methylprednisolone, and Antithymocyte Globulin in Treating Patients With Bone Marrow Failure Syndrome | completed | Phase 2 | 15 | Asan Medical CenterOTHER | 1 | Dec 31, 2015 | clinicaltrials |
| NCT01795378 | Safety and Efficacy Study of Donor Natural Killer Cells Given After Haploidentical Hematopoietic Cell Transplantation(DNKI-II) | completed | Phase 1 / Phase 2 | 56 | Asan Medical CenterOTHER | 1 | Dec 31, 2015 | clinicaltrials |
| NCT00630994 | Low-Dose Decitabine in Treating Patients With Symptomatic Myelofibrosis | terminated | Phase 2 | 4 | Mayo ClinicOTHER | 1 | Dec 30, 2015 | clinicaltrials |
| NCT00002718 | T-cell Depleted Bone Marrow and G-CSF Stimulated Peripheral Stem Cell Transplantation From Related Donors in Treating Patients With Leukemia, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, or Aplastic Anemia | completed | Phase 2 | 31 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 23, 2015 | clinicaltrials |
| NCT00028730 | Total-Body Irradiation and Chemotherapy Followed By Donor Bone Marrow Transplant in Treating Young Patients With Hematologic Cancer | completed | Phase 2 | 25 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 22, 2015 | clinicaltrials |
| NCT00866281 | A Study of the Safety and Preliminary Efficacy of Oral Midostaurin (PKC412) in Relapsed or Refractory Pediatric Leukemia | terminated | Phase 1 / Phase 2 | 22 | Novartis PharmaceuticalsINDUSTRY | 5 | Dec 22, 2015 | clinicaltrials |
| NCT01880437 | A Study of Vismodegib in Patients With Relapsed/Refractory Acute Myelogenous Leukemia and Relapsed Refractory High-Risk Myelodysplastic Syndrome | terminated | Phase 2 | 38 | Hoffmann-La RocheINDUSTRY | 3 | Dec 15, 2015 | clinicaltrials |
| NCT00188136 | Early Allogeneic Blood Stem Cell Transplantation in High-risk Acute Myeloid Leukemia (AML) | completed | Phase 2 | 32 | University Hospital Carl Gustav CarusOTHER | 1 | Dec 8, 2015 | clinicaltrials |
| NCT00062075 | Romidepsin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 2 | 47 | National Cancer Institute (NCI)NIH | 1 | Dec 4, 2015 | clinicaltrials |
| NCT00491634 | Treosulfan-based Conditioning for Transplantation in AML/MDS | completed | Phase 2 | 24 | Dr. Avichai Shimoni MDOTHER_GOV | 1 | Dec 2, 2015 | clinicaltrials |
| NCT01624701 | Clinical Ex Vivo Expansion of Human Umbilical Cord Blood Stem and Progenitor Cells | terminated | Phase 1 / Phase 2 | 3 | Singapore General HospitalOTHER | 1 | Nov 30, 2015 | clinicaltrials |
| NCT02034227 | Safety, Tolerability Study of SG2000 in the Treatment of Advanced Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 6 | SpirogenINDUSTRY | 1 | Nov 23, 2015 | clinicaltrials |
| NCT01211691 | Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF) | suspended | Phase 1 / Phase 2 | 120 | Humanigen, Inc.INDUSTRY | 2 | Nov 17, 2015 | clinicaltrials |
| NCT00299156 | Oral Clofarabine Study in Patients With Myelodysplastic Syndrome | completed | Phase 2 | 65 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 3, 2015 | clinicaltrials |
| NCT00670150 | New Retinoid Agent Combined With Arsenic Trioxide for Untreated Acute Promyelocytic Leukemia | withdrawn | Phase 2 | 0 | University of Southern CaliforniaOTHER | 1 | Oct 27, 2015 | clinicaltrials |
| NCT00241241 | Efficacy and Safety of Pegylated Interferon Alfa in Polycythemia Vera | completed | Phase 2 | 40 | PV-NordOTHER | 1 | Oct 21, 2015 | clinicaltrials |
| NCT00586651 | Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis | completed | Phase 2 | 39 | CephalonINDUSTRY | 1 | Oct 8, 2015 | clinicaltrials |
| NCT01295307 | Clofarabine Salvage Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)(BRIDGE) | completed | Phase 2 | 86 | Technische Universität DresdenOTHER | 1 | Oct 7, 2015 | clinicaltrials |
| NCT00134004 | Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer | completed | Phase 2 | 210 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 6, 2015 | clinicaltrials |
| NCT01794169 | Azacitidine Compared to Conventional Chemotherapy as Consolidation of Elderly Patients With AML | terminated | Phase 2 | 130 | Karolinska University HospitalOTHER | 1 | Sep 22, 2015 | clinicaltrials |
| NCT02502968 | BL-8040 Addition to Consolidation Therapy in AML Patients(BLAST) | unknown | Phase 2 | 194 | Dr. Petra TschanterOTHER | 1 | Sep 21, 2015 | clinicaltrials |
| NCT01802450 | Dasatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase(DASAPOST) | unknown | Phase 2 | 18 | PETHEMA FoundationOTHER | 1 | Sep 17, 2015 | clinicaltrials |
| NCT00866736 | A Study of Dasatinib in Patients With Imatinib Resistant or Intolerant Chronic Myeloid Leukemia | completed | Phase 2 | 65 | Kanto CML Study GroupOTHER | 1 | Sep 15, 2015 | clinicaltrials |
| NCT01342679 | A Study of Complete Molecular Response for Chronic Myeloid Leukemia in Chronic Phase Patients, Treated With Dasatinib(CMR-CML) | completed | Phase 2 | 21 | Kanto CML Study GroupOTHER | 1 | Sep 15, 2015 | clinicaltrials |
| NCT00086125 | Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED) | completed | Phase 2 | 57 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Aug 19, 2015 | clinicaltrials |
| NCT00588809 | Selumetinib in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia | completed | Phase 2 | 47 | National Cancer Institute (NCI)NIH | 1 | Aug 5, 2015 | clinicaltrials |
| NCT00407966 | Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | completed | Phase 2 | 45 | National Cancer Institute (NCI)NIH | 1 | Aug 4, 2015 | clinicaltrials |
| NCT02511340 | A Phase II Study to Evaluate the Efficacy and the Safety of Flumatinib in CML-AP or CML-BP Patients | unknown | Phase 2 | 167 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 30, 2015 | clinicaltrials |
| NCT00878722 | Trial of PXD101 (Belinostat) in Combination With Idarubicin to Treat AML Not Suitable for Standard Intensive Therapy | completed | Phase 1 / Phase 2 | 41 | Valerio TherapeuticsINDUSTRY | 3 | Jul 28, 2015 | clinicaltrials |
| NCT00565058 | Combination of GTI-2040 and Cytarabine in the Treatment of Refractory and Relapsed Acute Myeloid Leukemia (AML) | completed | Phase 2 | 27 | Aptose Biosciences Inc.INDUSTRY | 1 | Jul 27, 2015 | clinicaltrials |
Data updated 23 days agoSource updated Mar 4, 2016source: clinicaltrials